BioXcel Therapeutics Inc
BTAI2.990USD
-0.020-0.66%
Handelsschluss 09/19, 16:00（ET）Kurse um 15 Minuten verzögert
19.79MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über BioXcel Therapeutics Inc Unternehmen
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Company’s most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
Unternehmensinformationen
BörsenkürzelBTAI
Name des UnternehmensBioXcel Therapeutics Inc
IPO-datumMar 08, 2018
CEODr. Vimal Mehta, Ph.D.
Anzahl der mitarbeiter37
WertpapierartOrdinary Share
GeschäftsjahresendeMar 08
Addresse555 Long Wharf Dr
StadtNEW HAVEN
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl06511-6107
Telefon12036438060
Websitehttps://www.bioxceltherapeutics.com/
BörsenkürzelBTAI
IPO-datumMar 08, 2018
CEODr. Vimal Mehta, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. David J. Mack
Mr. David J. Mack
Independent Director
Independent Director
20.32K
+9.09%
Dr. Vimal Mehta, Ph.D.
Dr. Vimal Mehta, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
20.19K
+1.93%
Dr. Michal Votruba, M.D., Ph.D.
Dr. Michal Votruba, M.D., Ph.D.
Independent Director
Independent Director
11.52K
--
Dr. Peter Mueller, Ph.D.
Dr. Peter Mueller, Ph.D.
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
7.49K
-42.90%
Mr. Javier Rodriguez
Mr. Javier Rodriguez
Senior Vice President, Chief Legal Officer, Corporate Secretary
Senior Vice President, Chief Legal Officer, Corporate Secretary
6.73K
+1.02%
Mr. Richard I. Steinhart
Mr. Richard I. Steinhart
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
6.51K
+1.06%
Mr. Erik Kopp
Mr. Erik Kopp
Investor Relations
Investor Relations
--
--
DR. Frank D. Yocca ,Ph.D.
DR. Frank D. Yocca ,Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
--
--
Dr. Rajiv Patni, M.D.
Dr. Rajiv Patni, M.D.
Independent Director
Independent Director
--
--
Ms. June Bray
Ms. June Bray
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. David J. Mack
Mr. David J. Mack
Independent Director
Independent Director
20.32K
+9.09%
Dr. Vimal Mehta, Ph.D.
Dr. Vimal Mehta, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
20.19K
+1.93%
Dr. Michal Votruba, M.D., Ph.D.
Dr. Michal Votruba, M.D., Ph.D.
Independent Director
Independent Director
11.52K
--
Dr. Peter Mueller, Ph.D.
Dr. Peter Mueller, Ph.D.
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
7.49K
-42.90%
Mr. Javier Rodriguez
Mr. Javier Rodriguez
Senior Vice President, Chief Legal Officer, Corporate Secretary
Senior Vice President, Chief Legal Officer, Corporate Secretary
6.73K
+1.02%
Mr. Richard I. Steinhart
Mr. Richard I. Steinhart
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
6.51K
+1.06%
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sun, Aug 17
Aktualisiert: Sun, Aug 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Bioxcel Corp
2.44%
Armistice Capital LLC
1.47%
Oaktree Capital Management, L.P.
1.45%
Murchinson Ltd.
0.41%
UBS Financial Services, Inc.
0.20%
Andere
94.03%
Aktionäre
Aktionäre
Anteil
Bioxcel Corp
2.44%
Armistice Capital LLC
1.47%
Oaktree Capital Management, L.P.
1.45%
Murchinson Ltd.
0.41%
UBS Financial Services, Inc.
0.20%
Andere
94.03%
Aktionärstypen
Aktionäre
Anteil
Corporation
2.44%
Investment Advisor/Hedge Fund
2.00%
Hedge Fund
1.53%
Investment Advisor
0.72%
Individual Investor
0.42%
Research Firm
0.24%
Venture Capital
0.12%
Andere
92.53%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
225
1.20M
19.87%
-196.86K
2025Q1
248
1.19M
19.87%
-219.94K
2024Q4
260
1.00M
33.25%
-269.93K
2024Q3
269
724.21K
25.25%
-802.39K
2024Q2
282
1.14M
44.29%
-598.60K
2024Q1
282
1.17M
59.63%
-354.60K
2023Q4
282
1.17M
63.22%
-360.50K
2023Q3
290
1.23M
67.44%
-639.74K
2023Q2
289
1.71M
93.56%
-204.68K
2023Q1
297
1.69M
93.06%
-56.17K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Bioxcel Corp
480.34K
7.93%
-53.83K
-10.08%
Jun 06, 2024
Armistice Capital LLC
288.13K
4.76%
-24.20K
-7.75%
Mar 31, 2025
Murchinson Ltd.
136.08K
2.25%
+136.08K
--
Mar 31, 2025
UBS Financial Services, Inc.
101.78K
1.68%
+21.97K
+27.53%
Mar 31, 2025
Geode Capital Management, L.L.C.
22.06K
0.36%
+2.56K
+13.15%
Mar 31, 2025
Mack (David J)
16.93K
0.28%
+1.69K
+11.11%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Feb 06, 2025
Merger
16→1
Feb 06, 2025
Merger
16→1
Feb 06, 2025
Merger
16→1
Feb 06, 2025
Merger
16→1
Datum
Art
Verhältnis
Feb 06, 2025
Merger
16→1
Feb 06, 2025
Merger
16→1
Feb 06, 2025
Merger
16→1
Feb 06, 2025
Merger
16→1
